AR082644A1 - Tetranectina-apolipoproteina a-i, particulas lipidicas que la contiene y utilizacion de la misma relacionado con el metabolismo de los lipidos y las enfermedades cardiovasculares - Google Patents
Tetranectina-apolipoproteina a-i, particulas lipidicas que la contiene y utilizacion de la misma relacionado con el metabolismo de los lipidos y las enfermedades cardiovascularesInfo
- Publication number
- AR082644A1 AR082644A1 ARP110103103A ARP110103103A AR082644A1 AR 082644 A1 AR082644 A1 AR 082644A1 AR P110103103 A ARP110103103 A AR P110103103A AR P110103103 A ARP110103103 A AR P110103103A AR 082644 A1 AR082644 A1 AR 082644A1
- Authority
- AR
- Argentina
- Prior art keywords
- lipid
- apolipoprotein
- phosphatidylcholine
- tetranectina
- apolipoproteina
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
En la presente memoria se informa de una partícula lipídica que comprende una apolipoproteína, una fosfatidilcolina y un lípido, tal como un fosfolípido, ácido graso o lípido esteroide. En una realización, la partícula lipídica comprende únicamente un tipo de apolipoproteina. En una realización, la partícula lipídica consiste de una apolipoproteína, un fosfolípido, un lípido y un detergente. En una realización, el lípido es una segunda fosfatidilcolina, en el que la primera fosfatidilcolina y la segunda fosfatidilcolina difieren en uno o dos residuos ácido graso o derivados de residuo ácido graso que se encuentran esterificados con el esqueleto de glicerol de la fosfatidilcolina. En una realización, la apolipoproteína se selecciona de entre una apolipoproteína que presenta la secuencia de aminoácidos seleccionada de entre SEC ID Nº 01, 02, 06, 66 y 67, o es una variante de las mismas que presenta una identidad de secuencia de por lo menos 70% respecto a la secuencia seleccionada.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10008993 | 2010-08-30 | ||
| EP10188392 | 2010-10-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR082644A1 true AR082644A1 (es) | 2012-12-19 |
Family
ID=45773308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110103103A AR082644A1 (es) | 2010-08-30 | 2011-08-25 | Tetranectina-apolipoproteina a-i, particulas lipidicas que la contiene y utilizacion de la misma relacionado con el metabolismo de los lipidos y las enfermedades cardiovasculares |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9187550B2 (es) |
| EP (1) | EP2611418A2 (es) |
| JP (2) | JP5860052B2 (es) |
| KR (1) | KR101631363B1 (es) |
| CN (1) | CN103108626A (es) |
| AR (1) | AR082644A1 (es) |
| BR (1) | BR112013004395A2 (es) |
| CA (1) | CA2807448A1 (es) |
| MX (1) | MX2013002145A (es) |
| RU (1) | RU2013112562A (es) |
| TW (1) | TW201215394A (es) |
| WO (1) | WO2012028526A2 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012028526A2 (en) * | 2010-08-30 | 2012-03-08 | F. Hoffmann-La Roche Ag | Tetranectin-apolipoprotein a-i, lipid particles containing it and its use |
| JP6207507B2 (ja) | 2011-08-25 | 2017-10-04 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 短縮されたテトラネクチン−アポリポプロテインａ−ｉ融合タンパク質、それを含む脂質粒子、及びその使用 |
| CN103703015B (zh) | 2011-08-25 | 2019-07-05 | 霍夫曼-拉罗奇有限公司 | 阳离子和阴离子交换层析法 |
| EP2820031A1 (en) | 2012-02-29 | 2015-01-07 | F. Hoffmann-La Roche AG | On-column enzymatic cleavage |
| EP2959006B1 (en) * | 2013-02-22 | 2018-07-18 | F.Hoffmann-La Roche Ag | Use of an amino acid auxotrophy cured prokaryotic strain for the recombinant production of a polypeptide |
| JP2018516847A (ja) * | 2015-03-25 | 2018-06-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 生体高分子薬を送達するための組成物及び方法 |
| US11124558B2 (en) * | 2017-06-02 | 2021-09-21 | The Feinstein Institutes For Medical Research | Use of tetranectin and peptide agonists to treat inflammatory diseases |
| JP2020058343A (ja) * | 2018-10-05 | 2020-04-16 | 東ソー株式会社 | フコース結合性タンパク質の製造方法 |
| CN112546201A (zh) * | 2019-09-26 | 2021-03-26 | 中国科学院生物物理研究所 | 人工脂蛋白颗粒apoA-Ⅳ脂肪体在治疗和/或预防糖尿病中的应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07507554A (ja) * | 1992-06-12 | 1995-08-24 | エヌ・ブイ・イノゲネテイクス・エス・エイ | 新規ペプチドおよびタンパク質，それらの調製方法，ならびにコレステロール受容体としてのそれらの使用 |
| EP1012280B1 (en) | 1997-06-11 | 2004-11-10 | Borean Pharma A/S | Trimerising module |
| US6518412B1 (en) | 1997-09-29 | 2003-02-11 | Jean-Louis Dasseux | Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6291245B1 (en) | 1998-07-15 | 2001-09-18 | Roche Diagnostics Gmbh | Host-vector system |
| EP0972838B1 (en) | 1998-07-15 | 2004-09-15 | Roche Diagnostics GmbH | Escherichia coli host/vector system based on antibiotic-free selection by complementation of an auxotrophy |
| CA2406039A1 (en) | 2000-04-14 | 2001-10-25 | Hyseq, Inc. | Materials and methods relating to lipid metabolism |
| CN1268641C (zh) * | 2000-11-10 | 2006-08-09 | 普罗蒂奥制药公司 | 载脂蛋白类似物 |
| US7592008B2 (en) * | 2000-11-20 | 2009-09-22 | The Board Of Trustees Of The University Of Illinois, A Body Corporate And Politic Of The State Of Illinois | Membrane scaffold proteins |
| ITMI20021058A1 (it) * | 2002-05-17 | 2003-11-17 | Chiesi Farma Spa | Miscele di lipidi sintetici ottimizzate per la preparazione di un surfattante ricostituito |
| AU2003234625A1 (en) | 2002-05-17 | 2003-12-02 | Esperion Therapeutics, Inc. | Methods and copositions for the treatment of ischemic reperfusion |
| JP2006507223A (ja) * | 2002-05-17 | 2006-03-02 | エスペリオン セラピューティクス，インコーポレイテッド | 脂質代謝異常疾患の治療方法 |
| CA2443365C (en) | 2002-11-19 | 2010-01-12 | F. Hoffmann-La Roche Ag | Methods for the recombinant production of antifusogenic peptides |
| EP1486571B1 (en) | 2003-06-12 | 2005-12-14 | F. Hoffmann-La Roche Ag | Method for the recombinant production of polypeptides |
| PE20050438A1 (es) | 2003-10-20 | 2005-06-14 | Esperion Therapeutics Inc | Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos |
| WO2005084642A1 (en) | 2004-01-28 | 2005-09-15 | Biodelivery Sciences International, Inc. | Apoprotein cochleate compositions |
| US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
| KR100560102B1 (ko) | 2004-06-25 | 2006-03-13 | 한국생명공학연구원 | 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제 |
| US8206750B2 (en) * | 2005-03-24 | 2012-06-26 | Cerenis Therapeutics Holding S.A. | Charged lipoprotein complexes and their uses |
| EP1896074A4 (en) | 2005-05-25 | 2009-04-22 | Liponex Inc | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF CORONARY ARTERY DISEASE |
| US20070254832A1 (en) * | 2006-02-17 | 2007-11-01 | Pressler Milton L | Methods for the treatment of macular degeneration and related eye conditions |
| CA2653840A1 (en) | 2006-06-01 | 2007-12-06 | Institut De Cardiologie De Montreal | Use of a peptide/phospholipid complex acting as a reverse lipid transport agonist for treatment of valvular stenosis |
| CA2695951A1 (en) | 2006-08-10 | 2008-02-14 | Plantechno S.R.L. | In-plant production of dimeric and/or oligomeric (comprising three or more units) forms of human apo a-1 protein muteins |
| WO2008094905A2 (en) | 2007-01-29 | 2008-08-07 | Lipid Sciences, Inc. | Encapsulated hdl mimetic peptides |
| EP2118129A4 (en) | 2007-03-01 | 2010-04-28 | Life Technologies Corp | ISOLATED PHOSPHOLIPID PROTEIN PARTICLES |
| WO2008156873A2 (en) | 2007-06-20 | 2008-12-24 | Merck & Co., Inc. | Apoa-1 peptide mimetics |
| WO2009036460A2 (en) | 2007-09-14 | 2009-03-19 | Ambrx, Inc. | Modified human apolipoprotein a-i polypeptides and their uses |
| US8999320B2 (en) | 2008-01-30 | 2015-04-07 | The Rockefeller University | Nanoscale bound bilayers, methods of use and production |
| CN102036652B (zh) | 2008-04-25 | 2016-04-13 | 西北大学 | 适于螯合胆甾醇的纳米结构 |
| WO2010083611A1 (en) | 2009-01-23 | 2010-07-29 | Institut De Cardiologie De Montreal | Method for the prevention and treatment of diastolic dysfunction employing an apolipoproteina1 (apoa1) mimetic peptide/phospholipid complex |
| WO2012028526A2 (en) * | 2010-08-30 | 2012-03-08 | F. Hoffmann-La Roche Ag | Tetranectin-apolipoprotein a-i, lipid particles containing it and its use |
-
2011
- 2011-08-25 WO PCT/EP2011/064602 patent/WO2012028526A2/en active Application Filing
- 2011-08-25 US US13/217,534 patent/US9187550B2/en not_active Expired - Fee Related
- 2011-08-25 MX MX2013002145A patent/MX2013002145A/es unknown
- 2011-08-25 AR ARP110103103A patent/AR082644A1/es unknown
- 2011-08-25 JP JP2013526414A patent/JP5860052B2/ja not_active Expired - Fee Related
- 2011-08-25 CA CA2807448A patent/CA2807448A1/en not_active Abandoned
- 2011-08-25 EP EP11748408.9A patent/EP2611418A2/en not_active Withdrawn
- 2011-08-25 TW TW100130573A patent/TW201215394A/zh unknown
- 2011-08-25 RU RU2013112562/15A patent/RU2013112562A/ru not_active Application Discontinuation
- 2011-08-25 KR KR1020137007879A patent/KR101631363B1/ko active IP Right Grant
- 2011-08-25 BR BR112013004395A patent/BR112013004395A2/pt not_active IP Right Cessation
- 2011-08-25 CN CN2011800419518A patent/CN103108626A/zh active Pending
-
2015
- 2015-10-02 JP JP2015196701A patent/JP2016026186A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012028526A3 (en) | 2012-10-18 |
| TW201215394A (en) | 2012-04-16 |
| MX2013002145A (es) | 2013-04-03 |
| WO2012028526A2 (en) | 2012-03-08 |
| JP5860052B2 (ja) | 2016-02-16 |
| JP2013540106A (ja) | 2013-10-31 |
| JP2016026186A (ja) | 2016-02-12 |
| RU2013112562A (ru) | 2014-10-10 |
| BR112013004395A2 (pt) | 2019-09-24 |
| CA2807448A1 (en) | 2012-03-08 |
| CN103108626A (zh) | 2013-05-15 |
| KR20130059428A (ko) | 2013-06-05 |
| US20120190610A1 (en) | 2012-07-26 |
| EP2611418A2 (en) | 2013-07-10 |
| KR101631363B1 (ko) | 2016-06-17 |
| US9187550B2 (en) | 2015-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR082644A1 (es) | Tetranectina-apolipoproteina a-i, particulas lipidicas que la contiene y utilizacion de la misma relacionado con el metabolismo de los lipidos y las enfermedades cardiovasculares | |
| MX2015008199A (es) | Formulaciones de acido eicosapentaenoico (epa). | |
| Catalá | Lipid peroxidation modifies the picture of membranes from the “Fluid Mosaic Model” to the “Lipid Whisker Model” | |
| BR112014001907A2 (pt) | produção de dha e outros lc-pufas em plantas | |
| CO2018003678A2 (es) | Composiciones y métodos para inhibir la expresión génica de lpa | |
| AR097214A1 (es) | Composiciones edulcorantes | |
| CY1117367T1 (el) | Αντινοηματικο νουκλεϊνικο οξυ | |
| CO7061070A2 (es) | Composiciones enriquecidas con dpa de ácidos grasos omega 3 poliinsaturados en forma de ácido libre | |
| ES2667011T3 (es) | Monoacilgliceroles sn-2 y malabsorción lipídica | |
| MX2008014264A (es) | Esteres de glicerol estructurados utiles como barreras de humedad comestibles. | |
| CO6501136A2 (es) | Composiciones que comprenden una mezcla de aceite de ácido graso y un tensoactivo, y métodos y usos de las mismas | |
| NZ595856A (en) | Pharmaceutical composition | |
| AR098891A1 (es) | Proceso para obtener aceite microbiano a partir de células microbianas | |
| AR087745A1 (es) | Composiciones y metodos que comprenden una variante de enzima lipolitica | |
| PH12019501057A1 (en) | Oxidatively stable polyunsaturated fatty acid containing oil | |
| AU2018256637A1 (en) | Brassica rod1 gene sequences and uses thereof | |
| AR088294A1 (es) | Determinacion de polimorfismos de un nucleotido simple utiles para predecir la respuesta clinica al acetato de glatiramero | |
| WO2013136183A3 (en) | Oxidixable fatty acid composition delivery form | |
| CR9012A (es) | Compuestos de 4-amino-sustituido-2-sustituido-1,2,3,4-tetrahidroquinolina | |
| AR085325A1 (es) | PRODUCTOS NUTRICIONALES QUE COMPRENDEN b-HIDROXI-b-METILBUTIRATO | |
| NZ631131A (en) | Reconstituted hdl formulation | |
| MX2015007082A (es) | Métodos de administración de composiciones que comprenden ácido docosapentanoico. | |
| BR112012013010A2 (pt) | poliésteres de sacarose | |
| UY35856A (es) | Producción de acidos grasos poliinsaturados de cadena larga omega 3 en los cultivos de oleaginosas por una sintasa pufa traustoquitridio. | |
| BR112013032602A2 (pt) | poliésteres de sacarose |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |